ASX - By Stock
|
RAC |
Re:
Ann: Race to Present at TechKnow July Conference
|
|
RaceOncology
|
132 |
31K |
55 |
31/07/24 |
31/07/24 |
ASX - By Stock
|
132
|
31K
|
55
|
|
ASX - By Stock
|
RAC |
Re:
Ann: Race to Present at TechKnow July Conference
|
|
RaceOncology
|
132 |
31K |
29 |
31/07/24 |
31/07/24 |
ASX - By Stock
|
132
|
31K
|
29
|
|
ASX - By Stock
|
RAC |
Re:
Ann: Race to Present at TechKnow July Conference
|
|
RaceOncology
|
132 |
31K |
76 |
31/07/24 |
31/07/24 |
ASX - By Stock
|
132
|
31K
|
76
|
|
ASX - By Stock
|
RAC |
Re:
Ann: Race to Present at TechKnow July Conference
|
|
RaceOncology
|
132 |
31K |
15 |
25/07/24 |
25/07/24 |
ASX - By Stock
|
132
|
31K
|
15
|
|
ASX - By Stock
|
RAC |
Re:
Ann: Race to Present at TechKnow July Conference
|
|
RaceOncology
|
132 |
31K |
18 |
25/07/24 |
25/07/24 |
ASX - By Stock
|
132
|
31K
|
18
|
|
ASX - By Stock
|
RAC |
Re:
Race Oncology - Cashflow Forecast to December 2024
|
|
RaceOncology
|
27 |
9.1K |
115 |
25/07/24 |
25/07/24 |
ASX - By Stock
|
27
|
9.1K
|
115
|
|
ASX - By Stock
|
RAC |
Re:
Ann: Race to Present at TechKnow July Conference
|
|
RaceOncology
|
132 |
31K |
52 |
25/07/24 |
25/07/24 |
ASX - By Stock
|
132
|
31K
|
52
|
|
ASX - By Stock
|
RAC |
Re:
Ann: Quarterly Activity Report and Appendix 4C
|
|
RaceOncology
|
34 |
10K |
93 |
23/07/24 |
23/07/24 |
ASX - By Stock
|
34
|
10K
|
93
|
|
General
|
RAC |
Re:
General Comments / Chat
|
|
RaceOncology
|
11K |
3.9M |
32 |
23/07/24 |
23/07/24 |
General
|
11K
|
3.9M
|
32
|
|
ASX - By Stock
|
RAC |
Re:
Ann: Quarterly Activity Report and Appendix 4C
|
|
RaceOncology
|
34 |
10K |
56 |
23/07/24 |
23/07/24 |
ASX - By Stock
|
34
|
10K
|
56
|
|
ASX - By Stock
|
RAC |
Re:
Cardioprotection thread
|
|
RaceOncology
|
905 |
268K |
101 |
22/07/24 |
22/07/24 |
ASX - By Stock
|
905
|
268K
|
101
|
|
ASX - By Stock
|
RAC |
Re:
Cardioprotection thread
|
|
RaceOncology
|
905 |
268K |
78 |
22/07/24 |
22/07/24 |
ASX - By Stock
|
905
|
268K
|
78
|
|
ASX - By Stock
|
RAC |
Re:
Cardioprotection thread
|
|
RaceOncology
|
905 |
268K |
48 |
22/07/24 |
22/07/24 |
ASX - By Stock
|
905
|
268K
|
48
|
|
ASX - By Stock
|
RAC Biotech |
Re:
RAC - Charts & Price Action
|
|
RaceOncology
|
22K |
7.6M |
11 |
19/07/24 |
19/07/24 |
ASX - By Stock
|
22K
|
7.6M
|
11
|
|
ASX - By Stock
|
RAC Biotech |
Re:
RAC - Charts & Price Action
|
|
RaceOncology
|
22K |
7.6M |
30 |
19/07/24 |
19/07/24 |
ASX - By Stock
|
22K
|
7.6M
|
30
|
|
ASX - By Stock
|
RAC Biotech |
Re:
RAC - Charts & Price Action
|
|
RaceOncology
|
22K |
7.6M |
27 |
19/07/24 |
19/07/24 |
ASX - By Stock
|
22K
|
7.6M
|
27
|
|
ASX - By Stock
|
RAC Biotech |
Re:
RAC - Charts & Price Action
|
|
RaceOncology
|
22K |
7.6M |
15 |
19/07/24 |
19/07/24 |
ASX - By Stock
|
22K
|
7.6M
|
15
|
|
ASX - By Stock
|
RAC |
Re:
Ann: Race Appoints George Clinical for Phase 1 Trial of RC220
|
|
RaceOncology
|
146 |
44K |
36 |
18/07/24 |
18/07/24 |
ASX - By Stock
|
146
|
44K
|
36
|
|
ASX - By Stock
|
RAC |
Re:
Ann: Race Appoints George Clinical for Phase 1 Trial of RC220
|
|
RaceOncology
|
146 |
44K |
34 |
18/07/24 |
18/07/24 |
ASX - By Stock
|
146
|
44K
|
34
|
|
ASX - By Stock
|
RAC |
Re:
Ann: Race Appoints George Clinical for Phase 1 Trial of RC220
|
|
RaceOncology
|
146 |
44K |
58 |
17/07/24 |
17/07/24 |
ASX - By Stock
|
146
|
44K
|
58
|
|
ASX - By Stock
|
RAC |
Re:
Ann: Race Appoints George Clinical for Phase 1 Trial of RC220
|
|
RaceOncology
|
146 |
44K |
47 |
16/07/24 |
16/07/24 |
ASX - By Stock
|
146
|
44K
|
47
|
|
ASX - By Stock
|
RAC |
Re:
RAC - Crystal ball gazing
|
|
RaceOncology
|
38 |
7.9K |
37 |
15/07/24 |
15/07/24 |
ASX - By Stock
|
38
|
7.9K
|
37
|
|
ASX - By Stock
|
RAC |
Re:
RAC - Crystal ball gazing
|
|
RaceOncology
|
38 |
7.9K |
26 |
15/07/24 |
15/07/24 |
ASX - By Stock
|
38
|
7.9K
|
26
|
|
ASX - By Stock
|
RAC |
Re:
Ann: Distinguished Oncologist Daniel Von Hoff Joins as Consultant
|
|
RaceOncology
|
168 |
47K |
20 |
15/07/24 |
15/07/24 |
ASX - By Stock
|
168
|
47K
|
20
|
|
ASX - By Stock
|
RAC |
Re:
Ann: Race Appoints George Clinical for Phase 1 Trial of RC220
|
|
RaceOncology
|
146 |
44K |
52 |
15/07/24 |
15/07/24 |
ASX - By Stock
|
146
|
44K
|
52
|
|
ASX - By Stock
|
RAC |
Re:
Ann: Race Appoints George Clinical for Phase 1 Trial of RC220
|
|
RaceOncology
|
146 |
44K |
20 |
15/07/24 |
15/07/24 |
ASX - By Stock
|
146
|
44K
|
20
|
|
ASX - By Stock
|
RAC |
Re:
Ann: Race Appoints George Clinical for Phase 1 Trial of RC220
|
|
RaceOncology
|
146 |
44K |
73 |
15/07/24 |
15/07/24 |
ASX - By Stock
|
146
|
44K
|
73
|
|
ASX - By Stock
|
RAC |
Re:
Ann: Race Appoints George Clinical for Phase 1 Trial of RC220
|
|
RaceOncology
|
146 |
44K |
63 |
15/07/24 |
15/07/24 |
ASX - By Stock
|
146
|
44K
|
63
|
|
ASX - By Stock
|
RAC |
Re:
Ann: Race Appoints George Clinical for Phase 1 Trial of RC220
|
|
RaceOncology
|
146 |
44K |
51 |
15/07/24 |
15/07/24 |
ASX - By Stock
|
146
|
44K
|
51
|
|
ASX - By Stock
|
RAC |
Re:
Ann: Race Appoints George Clinical for Phase 1 Trial of RC220
|
|
RaceOncology
|
146 |
44K |
20 |
15/07/24 |
15/07/24 |
ASX - By Stock
|
146
|
44K
|
20
|
|
ASX - By Stock
|
RAC |
Re:
Ann: Race Appoints George Clinical for Phase 1 Trial of RC220
|
|
RaceOncology
|
146 |
44K |
95 |
14/07/24 |
14/07/24 |
ASX - By Stock
|
146
|
44K
|
95
|
|
ASX - By Stock
|
RAC |
Re:
Cardioprotection thread
|
|
RaceOncology
|
905 |
268K |
26 |
14/07/24 |
14/07/24 |
ASX - By Stock
|
905
|
268K
|
26
|
|
ASX - By Stock
|
RAC |
Re:
Cardioprotection thread
|
|
RaceOncology
|
905 |
268K |
62 |
14/07/24 |
14/07/24 |
ASX - By Stock
|
905
|
268K
|
62
|
|
ASX - By Stock
|
RAC |
Re:
Ann: Race Appoints George Clinical for Phase 1 Trial of RC220
|
|
RaceOncology
|
146 |
44K |
54 |
14/07/24 |
14/07/24 |
ASX - By Stock
|
146
|
44K
|
54
|
|
ASX - By Stock
|
RAC |
Re:
Ann: Race In-person Investor Briefing Invitation Perth
|
|
RaceOncology
|
130 |
37K |
33 |
11/07/24 |
11/07/24 |
ASX - By Stock
|
130
|
37K
|
33
|
|
ASX - By Stock
|
RAC |
Re:
Q. Bisantrene is not new. How can RAC monetise if it is out of patent?
|
|
RaceOncology
|
391 |
80K |
93 |
11/07/24 |
11/07/24 |
ASX - By Stock
|
391
|
80K
|
93
|
|
ASX - By Stock
|
RAC |
Re:
Ann: Race In-person Investor Briefing Invitation Perth
|
|
RaceOncology
|
130 |
37K |
51 |
11/07/24 |
11/07/24 |
ASX - By Stock
|
130
|
37K
|
51
|
|
ASX - By Stock
|
RAC |
Re:
Q. Bisantrene is not new. How can RAC monetise if it is out of patent?
|
|
RaceOncology
|
391 |
80K |
108 |
09/07/24 |
09/07/24 |
ASX - By Stock
|
391
|
80K
|
108
|
|
ASX - By Stock
|
RAC |
Re:
Q. Bisantrene is not new. How can RAC monetise if it is out of patent?
|
|
RaceOncology
|
391 |
80K |
29 |
09/07/24 |
09/07/24 |
ASX - By Stock
|
391
|
80K
|
29
|
|
ASX - By Stock
|
RAC |
Re:
Q. Bisantrene is not new. How can RAC monetise if it is out of patent?
|
|
RaceOncology
|
391 |
80K |
63 |
09/07/24 |
09/07/24 |
ASX - By Stock
|
391
|
80K
|
63
|
|
ASX - By Stock
|
RAC |
Re:
Q. Bisantrene is not new. How can RAC monetise if it is out of patent?
|
|
RaceOncology
|
391 |
80K |
85 |
08/07/24 |
08/07/24 |
ASX - By Stock
|
391
|
80K
|
85
|
|
ASX - By Stock
|
RAC |
Re:
Q. Bisantrene is not new. How can RAC monetise if it is out of patent?
|
|
RaceOncology
|
391 |
80K |
44 |
08/07/24 |
08/07/24 |
ASX - By Stock
|
391
|
80K
|
44
|
|
ASX - By Stock
|
RAC |
Re:
Q. Bisantrene is not new. How can RAC monetise if it is out of patent?
|
|
RaceOncology
|
391 |
80K |
33 |
08/07/24 |
08/07/24 |
ASX - By Stock
|
391
|
80K
|
33
|
|
ASX - By Stock
|
RAC |
Re:
Q. Bisantrene is not new. How can RAC monetise if it is out of patent?
|
|
RaceOncology
|
391 |
80K |
32 |
08/07/24 |
08/07/24 |
ASX - By Stock
|
391
|
80K
|
32
|
|
ASX - By Stock
|
RAC |
Re:
Q. Bisantrene is not new. How can RAC monetise if it is out of patent?
|
|
RaceOncology
|
391 |
80K |
37 |
08/07/24 |
08/07/24 |
ASX - By Stock
|
391
|
80K
|
37
|
|
General
|
RAC |
Re:
General Comments / Chat
|
|
RaceOncology
|
11K |
3.9M |
42 |
08/07/24 |
08/07/24 |
General
|
11K
|
3.9M
|
42
|
|
ASX - By Stock
|
RAC |
Re:
Q. Bisantrene is not new. How can RAC monetise if it is out of patent?
|
|
RaceOncology
|
391 |
80K |
34 |
08/07/24 |
08/07/24 |
ASX - By Stock
|
391
|
80K
|
34
|
|
ASX - By Stock
|
RAC |
Re:
Ann: Distinguished Oncologist Daniel Von Hoff Joins as Consultant
|
|
RaceOncology
|
168 |
47K |
11 |
08/07/24 |
08/07/24 |
ASX - By Stock
|
168
|
47K
|
11
|
|
ASX - By Stock
|
RAC |
Q. Bisantrene is not new. How can RAC monetise if it is out of patent?
|
|
RaceOncology
|
391 |
80K |
108 |
07/07/24 |
07/07/24 |
ASX - By Stock
|
391
|
80K
|
108
|
|
ASX - By Stock
|
RAC |
Re:
RAC media coverage
|
|
RaceOncology
|
2.2K |
767K |
47 |
03/07/24 |
03/07/24 |
ASX - By Stock
|
2.2K
|
767K
|
47
|
|